Predicting excellent response to radioiodine in differentiated thyroid cancer using machine learning

被引:0
|
作者
Bulbul, Ogun [1 ]
Nak, Demet [1 ]
机构
[1] Recep Tayyip Erdogan Univ, Training & Res Hosp, Fac Med, Dept Nucl Med, Rize, Turkiye
关键词
machine learning; excellent response; prediction; radioactive iodine; differentiated thyroid cancer; RADIOACTIVE IODINE THERAPY; REMNANT ABLATION; INTERMEDIATE-RISK; THYROGLOBULIN; SURVIVAL; CARCINOMA; FAILURE; IMPACT;
D O I
10.14639/0392-100X-N3029
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective. If excellent response (ER) occurs after radioactive iodine (RAI) treatment in patients with differentiated thyroid carcinoma (DTC), the recurrence rate is low. Our study aims to predict ER at 6-24 months after RAI I by using machine learning (ML) methods in which clinicopathological parameters are included in patients with DTC without distant metastasis. Methods. Treatment response of 151 patients with DTC without distant metastasis and who received RAI treatment was determined (ER/nonER). Thyroidectomy +/- neck dissection pathology data, laboratory, and imaging findings before and after RAI treatment were introduced to ML models. Results. After RAI treatment, 118 patients had ER and 33 had nonER. Before RAI treatment, TgAb was positive in 29% of patients with ER and 55% of patients with nonER (p = 0.007). Eight of the ML models predicted ER with high area under the ROC curve (AUC) values (> 0.700). The model with the highest AUC value was extreme gradient boosting (AUC = 0.871), the highest accuracy shown by gradient boosting (81%). Conclusions. ML models may be used to predict ER in patients with DTC without distant metastasis.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 50 条
  • [21] Risk management of radioiodine treatment in differentiated thyroid cancer
    Villena-Salinas, J.
    Alcocer, M. A. Sempere
    Peinado, M. Gallego
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2024, 43 (04):
  • [22] Radioiodine therapy in the different stages of differentiated thyroid cancer
    Valerio, Laura
    Maino, Fabio
    Castagna, Maria Grazia
    Pacini, Furio
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (01)
  • [23] Treatment strategy by radioiodine refractory differentiated thyroid cancer
    Mantsopoulos, Konstantinos
    Mueller, Sarina K.
    Pavel, Marianne
    Kuwert, Torsten
    Meidenbauer, Norbert
    Fietkau, Rainer
    Sievert, Matti
    Iro, Heinrich
    LARYNGO-RHINO-OTOLOGIE, 2022, 101 (04) : 298 - 303
  • [24] Advanced Radioiodine-refractory differentiated Thyroid Cancer
    Spitzweg, Christine
    Auernhammer, Christoph J.
    Geisler, Julia
    Boeck, Stefan
    Heinemann, Volker
    Bartenstein, Peter
    Goeke, Burkhard
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (03) : 168 - 171
  • [25] The Evolving Use of Radioiodine Therapy in Differentiated Thyroid Cancer
    Mayson, Sarah E.
    Yoo, Don C.
    Gopalakrishnan, Geetha
    ONCOLOGY, 2015, 88 (04) : 247 - 256
  • [26] Indications and results of radioiodine treatment of differentiated thyroid cancer
    Riemann, B.
    CHIRURG, 2020, 91 (12): : 1013 - 1016
  • [27] Enhancing Techniques for Radioiodine Imaging of Differentiated Thyroid Cancer
    Lima, Cristiane Jeyce Gomes
    Wu, Di
    Turner, Deniek
    Burman, Kenneth
    Van Nostrand, Douglas
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [28] THE USE OF RADIOIODINE IN THE MANAGEMENT OF THE DIFFERENTIATED THYROID-CANCER
    BESTAGNO, MF
    PAGLIAINI, R
    MAIRA, G
    TERZI, A
    JOURNAL OF RADIOANALYTICAL CHEMISTRY, 1981, 65 (1-2): : 239 - 249
  • [29] Cabozantinib for radioiodine-refractory differentiated thyroid cancer
    Chiapponi, Costanza
    Hartmann, Milan J. M.
    Hescheler, Daniel A.
    Alakus, Hakan
    ONKOLOGE, 2021, 27 (12): : 1241 - 1242
  • [30] RADIOIODINE AND RADIOTHERAPY IN TREATING DIFFERENTIATED THYROID-CANCER
    SIMPSON, WJ
    PANZARELLA, T
    CARRUTHERS, JS
    GOSPODAROWICZ, MK
    SUTCLIFFE, SB
    MCKINNEY, SE
    CLINICAL AND INVESTIGATIVE MEDICINE, 1987, 10 (04): : B113 - B113